Zealand Pharma shares leap after Wells Fargo’s new Buy coverage
Investing.com -- Wells Fargo has initiated coverage of Zealand Pharma (NASDAQ:ZEAL) with an Overweight rating and a DKK 650 price target, seeing the Danish biotech as poised to become “a key obesity player” thanks to its differentiated pipeline targeting the rapidly expanding weight loss market.